| Name | Title | Contact Details |
|---|
Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. Its Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. The company’s platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. It has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. The company’s products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA for the treatment of prostate cancer; and ADXS-cHER2 for the treatment of overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Marina Biotech`s focus is to treat the intersection of arthritis, pain, hypertension, and oncology diseases using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. The company`s `next-generation of celecoxib,` including IT-102 and IT-103, are designed to control the dangerous side-effect of edema that prohibits the drug from being prescribed at higher doses. These have the potential of replacing opioids and combating the opioid epidemic. They are also being developed as anticancer agents against FAP and CRC. On the Sales and Marketing front- we are actively promoting sales and distribution of our FDA approved drug- Prestalia- through our patient centric care program: 1) We have developed a patented total care program which increase compliance to over 80%. 2) Increase compliance is expected to improve care for hypertensive patients, especially resistant hypertensive patients which currently have no treatment available to them. 3) Resistant hypertension market size is large with 22% of all hypertensive pts eventually become resistant hypertension 4) Compliance/counseling has been shown clinically to treated resistant hypertensive patients 5) Deep pipeline a. Perindopril- Hypertension monotherapy. ACEON (Perindopril) NDA b. Prestalia- Hypertension combination therapy. i. Perindopril/Amlodipine, ii. 1st line hypertension, c. Atorvastatin/Perindopril: Hypertension and lipid disorder d. Pipeline drug: Hypertension and Pain. IT-102, IT-103
GenVec is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Radient Pharmaceuticals Corporation is a Tustin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharmative is a Northridge, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.